Skip to main content
. 2023 Jan 25;4(4):225–231. doi: 10.1016/j.hroo.2023.01.004

Table 3.

Factors associated with improvement in LVEF postupgrade

Univariate
Multivariate
LVEF increase (%) 95% CI (%) P Value LVEF increase (%) 95% CI (%) P Value
Female 0.30 –5.76 to 6.29 .93
Age –0.22 –0.47 to 0.03 .08 –0.18 –0.43 to 0.08 .18
Coronary artery disease –0.21 –5.74 to 5.33 .94
Atrial fibrillation 0.67 –4.86 to 6.20 .81
Clinical heart failure 7.45 –0.86 to 15.76 .08
Beta-blocker use 0.71 –6.39 to 7.82 .84
ACE inhibitor or ARB use 7.16 1.42 to 12.91 .02 7.21 –0.10 to 14.53 .05
MRA use 7.54 2.33 to 12.74 .01 4.51 –1.57 to 10.59 .14
Loop diuretic use 0.89 –4.91 to 6.69 .76
Pacemaker indication—complete heart block –3.87 –12.42 to 4.68 .37
CRT defibrillator implantation 3.49 –2.75 to 9.74 .27
Right ventricular pacing percentage –0.05 –0.08 to 0.17 .46
LBBB –1.64 –9.61 to 6.33 .68
RBBB 7.63 –1.59 to 16.85 .10
Time to PICM –0.01 –0.04 to 0.02 .64
Time from PICM to upgrade –0.43 –1.22 to 0.36 .27
Need for venuloplasty during upgrade 2.50 –4.00 to 9.00 .44
Native QRS 0.01 –0.14 to 0.16 .90
Preupgrade paced QRS 0.06 –0.05 to 0.18 .26
Postupgrade paced QRS –0.06 –0.17 to 0.06 .30
Change in QRS postupgrade –0.06 –0.18 to 0.05 .28
Preupgrade EF –0.42 –0.72 to –0.11 .01 –0.26 –0.65 to 0.13 0.18
Preupgrade LVIDd 2.31 –1.15 to 5.77 .18
RV septal lead placement 2.71 0.23 to 32.34 .43

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CI = confidence interval; CRT = cardiac resynchronization therapy; EF = ejection fraction; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; LVIDd = left ventricular end-diastolic diameter; MRA = mineralocorticoid receptor antagonist; PICM = pacing-induced cardiomyopathy; RBBB = right bundle branch block; RV = right ventricular.